绝食还能抑制癌症呢_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

函盖乾坤截断众流随波逐浪
05-22

绝食还能抑制癌症呢

减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好

四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。

减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":566775408767744,"tweetId":"566775408767744","gmtCreate":1779407212953,"gmtModify":1779414841787,"author":{"id":3544441872957647,"idStr":"3544441872957647","authorId":3544441872957647,"authorIdStr":"3544441872957647","name":"函盖乾坤截断众流随波逐浪","avatar":"https://static.tigerbbs.com/f4602544b3ccc4c41a2be942e28cbf75","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":304,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":228,"starInvestorOrderShareNum":214,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":68.93,"showRor":true,"investmentPhilosophy":"内求、无漏","winRationPercentage":40,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>绝食还能抑制癌症呢</p></body></html>","htmlText":"<html><head></head><body><p>绝食还能抑制癌症呢</p></body></html>","text":"绝食还能抑制癌症呢","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/566775408767744","repostId":2637336886,"repostType":4,"repost":{"id":"2637336886","kind":"highlight","weMediaInfo":{"introduction":"追踪全球财经热点，精选影响您财富的资讯，投资理财必备神器！","home_visible":1,"media_name":"华尔街见闻","id":"1084101182","head_image":"https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e"},"pubTimestamp":1779403947,"share":"https://www.laohu8.com/m/news/2637336886?lang=zh_CN&edition=full","pubTime":"2026-05-22 06:52","market":"other","language":"zh","title":"减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336886","media":"华尔街见闻","summary":"四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。","content":"<html><head></head><body><blockquote><p style=\"text-align: left;\">四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。</p></blockquote><p style=\"text-align: justify;\">全球最畅销的减重与糖尿病药物或将迎来又一重大突破。</p><p style=\"text-align: justify;\">四项新研究显示，<strong>诺和诺德的Ozempic和礼来的Mounjaro等GLP-1类药物，与癌症患者更好的治疗结局之间存在关联</strong>，可能进一步扩大这类已拥有数以千万用户的药物的市场前景，并为上述两家全球市值最高的制药公司提供新的增长动力。</p><p style=\"text-align: justify;\">上述研究将于本月晚些时候在美国临床肿瘤学会（ASCO）年会上发布，涵盖逾数十万名患者的数据。</p><p style=\"text-align: justify;\">其中规模最大的研究来自克利夫兰诊所癌症研究所，追踪逾1万名早期癌症患者，结果显示GLP-1药物使用者的癌症进展风险显著低于对比组——<strong>肺癌患者疾病进展率约减半，乳腺癌患者进展率同样从20%降至10%。</strong></p><p style=\"text-align: justify;\">另有研究显示，<strong>乳腺癌GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。</strong></p><p style=\"text-align: justify;\">若抗癌效益最终得到证实，将进一步巩固诺和诺德与礼来的行业地位。GLP-1药物已获批用于降低心脏病发作和中风风险，并正在测试对睡眠呼吸暂停及成瘾行为的疗效，抗癌效益将再度扩展这类药物的医学价值边界，并可能重塑其定价与报销逻辑。</p><p style=\"text-align: justify;\">然而，研究人员明确指出，<strong>现有证据仅显示关联性，而非因果关系。</strong>四项研究均为回顾性观察研究，依赖保险理赔记录和医疗数据库，尚需随机对照试验加以确认。目前，诺和诺德与礼来均未针对GLP-1药物的抗癌效果开展专项临床研究。</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>多癌种进展率大幅下降，数据信号一致</strong></h2><p style=\"text-align: justify;\">克利夫兰诊所癌症研究所的研究将逾1万名确诊早期癌症后开始使用GLP-1药物的患者，与使用其他糖尿病药物的患者进行对比，结果显示GLP-1使用者的癌症扩散风险更低。</p><p style=\"text-align: justify;\">具体数据颇为引人关注：肺癌患者中，进展为晚期的比例在GLP-1组约为10%，对比组为22%，降幅约50%；乳腺癌患者进展率分别为10%和20%；结直肠癌和肝癌亦呈现具有统计学意义的下降。</p><p style=\"text-align: justify;\">&#34;鉴于数以百万计的美国人正在使用GLP-1类药物，我们显然迫切需要了解其潜在的抗肿瘤效果，&#34;将在ASCO年会上发布上述研究的克利夫兰诊所住院医生Dr. Mark Orland表示。</p><p style=\"text-align: justify;\">未参与任何相关研究的Dana-Farber癌症研究所乳腺肿瘤学家Dr. Jennifer Ligibel表示，&#34;在多种癌症中，使用这些药物的人似乎癌症复发风险更低，这一发现确实令人瞩目。&#34;</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>乳腺癌数据：发病率与生存率双双改善</strong></h2><p style=\"text-align: justify;\">另外两项研究专门聚焦乳腺癌，从发病率和生存率两个维度考察GLP-1药物的潜在作用。</p><p style=\"text-align: justify;\">德克萨斯大学MD安德森癌症中心对逾13.7万名乳腺癌患者的分析显示，GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。</p><p style=\"text-align: justify;\">宾夕法尼亚大学的研究纳入近9.5万名接受乳腺影像检查的女性，发现曾使用GLP-1药物者被诊断为乳腺癌的风险低约25%，这一差异在控制年龄、体重及其他风险因素后依然成立。</p><p style=\"text-align: justify;\">MD安德森乳腺肿瘤学家、上述生存率研究的参与者Dr. Jasmine Sukumar表示：&#34;我们在多个数据库中都观察到了信号，这确实值得关注，因为这些研究的设计各有不同。&#34;</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>作用机制存争议：代谢改善还是直接靶向肿瘤？</strong></h2><p style=\"text-align: justify;\">科学界目前对GLP-1药物为何可能产生抗癌效果尚无定论，主要存在两种假说。</p><p style=\"text-align: justify;\">其一，GLP-1药物通过推动减重和改善代谢健康间接降低癌症风险，而体重控制和代谢健康本身均与更低的癌症发病率独立相关。</p><p style=\"text-align: justify;\">其二，GLP-1——即这类药物所模拟的激素——的受体存在于部分肿瘤细胞表面，暗示药物可能直接作用于癌症的生物学过程本身。无论哪种机制最终得到证实，均对这类药物的长期医学与商业价值具有重要意义。</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>观察性研究局限不容忽视，确认仍需随机试验</strong></h2><p style=\"text-align: justify;\">尽管数据信号具有一致性，研究人员仍对现有研究的局限性保持审慎。</p><p style=\"text-align: justify;\">四项研究均依赖回顾性保险理赔记录和医疗数据库，存在固有偏差风险：被处方GLP-1药物的患者往往拥有更好的医疗资源获取渠道和更稳定的随访记录，这些因素本身就可能独立改善治疗结局，难以与药物效果剥离。</p><p style=\"text-align: justify;\">要确认GLP-1药物自身是否驱动了上述获益，需要通过随机对照试验——严格控制收入水平、基础健康状况及医疗资源差异的研究设计——加以验证。</p><p style=\"text-align: justify;\">目前，诺和诺德与礼来均未启动针对癌症适应症的专项研究。尽管如此，克利夫兰诊所癌症研究所副主席、相关研究的主导者Dr. Jaroslaw Maciejewski表示，横跨数十万患者的一致性数据&#34;很难被忽视&#34;。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1084101182\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">华尔街见闻 </p>\n<p class=\"h-time\">2026-05-22 06:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><blockquote><p style=\"text-align: left;\">四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。</p></blockquote><p style=\"text-align: justify;\">全球最畅销的减重与糖尿病药物或将迎来又一重大突破。</p><p style=\"text-align: justify;\">四项新研究显示，<strong>诺和诺德的Ozempic和礼来的Mounjaro等GLP-1类药物，与癌症患者更好的治疗结局之间存在关联</strong>，可能进一步扩大这类已拥有数以千万用户的药物的市场前景，并为上述两家全球市值最高的制药公司提供新的增长动力。</p><p style=\"text-align: justify;\">上述研究将于本月晚些时候在美国临床肿瘤学会（ASCO）年会上发布，涵盖逾数十万名患者的数据。</p><p style=\"text-align: justify;\">其中规模最大的研究来自克利夫兰诊所癌症研究所，追踪逾1万名早期癌症患者，结果显示GLP-1药物使用者的癌症进展风险显著低于对比组——<strong>肺癌患者疾病进展率约减半，乳腺癌患者进展率同样从20%降至10%。</strong></p><p style=\"text-align: justify;\">另有研究显示，<strong>乳腺癌GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。</strong></p><p style=\"text-align: justify;\">若抗癌效益最终得到证实，将进一步巩固诺和诺德与礼来的行业地位。GLP-1药物已获批用于降低心脏病发作和中风风险，并正在测试对睡眠呼吸暂停及成瘾行为的疗效，抗癌效益将再度扩展这类药物的医学价值边界，并可能重塑其定价与报销逻辑。</p><p style=\"text-align: justify;\">然而，研究人员明确指出，<strong>现有证据仅显示关联性，而非因果关系。</strong>四项研究均为回顾性观察研究，依赖保险理赔记录和医疗数据库，尚需随机对照试验加以确认。目前，诺和诺德与礼来均未针对GLP-1药物的抗癌效果开展专项临床研究。</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>多癌种进展率大幅下降，数据信号一致</strong></h2><p style=\"text-align: justify;\">克利夫兰诊所癌症研究所的研究将逾1万名确诊早期癌症后开始使用GLP-1药物的患者，与使用其他糖尿病药物的患者进行对比，结果显示GLP-1使用者的癌症扩散风险更低。</p><p style=\"text-align: justify;\">具体数据颇为引人关注：肺癌患者中，进展为晚期的比例在GLP-1组约为10%，对比组为22%，降幅约50%；乳腺癌患者进展率分别为10%和20%；结直肠癌和肝癌亦呈现具有统计学意义的下降。</p><p style=\"text-align: justify;\">&#34;鉴于数以百万计的美国人正在使用GLP-1类药物，我们显然迫切需要了解其潜在的抗肿瘤效果，&#34;将在ASCO年会上发布上述研究的克利夫兰诊所住院医生Dr. Mark Orland表示。</p><p style=\"text-align: justify;\">未参与任何相关研究的Dana-Farber癌症研究所乳腺肿瘤学家Dr. Jennifer Ligibel表示，&#34;在多种癌症中，使用这些药物的人似乎癌症复发风险更低，这一发现确实令人瞩目。&#34;</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>乳腺癌数据：发病率与生存率双双改善</strong></h2><p style=\"text-align: justify;\">另外两项研究专门聚焦乳腺癌，从发病率和生存率两个维度考察GLP-1药物的潜在作用。</p><p style=\"text-align: justify;\">德克萨斯大学MD安德森癌症中心对逾13.7万名乳腺癌患者的分析显示，GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。</p><p style=\"text-align: justify;\">宾夕法尼亚大学的研究纳入近9.5万名接受乳腺影像检查的女性，发现曾使用GLP-1药物者被诊断为乳腺癌的风险低约25%，这一差异在控制年龄、体重及其他风险因素后依然成立。</p><p style=\"text-align: justify;\">MD安德森乳腺肿瘤学家、上述生存率研究的参与者Dr. Jasmine Sukumar表示：&#34;我们在多个数据库中都观察到了信号，这确实值得关注，因为这些研究的设计各有不同。&#34;</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>作用机制存争议：代谢改善还是直接靶向肿瘤？</strong></h2><p style=\"text-align: justify;\">科学界目前对GLP-1药物为何可能产生抗癌效果尚无定论，主要存在两种假说。</p><p style=\"text-align: justify;\">其一，GLP-1药物通过推动减重和改善代谢健康间接降低癌症风险，而体重控制和代谢健康本身均与更低的癌症发病率独立相关。</p><p style=\"text-align: justify;\">其二，GLP-1——即这类药物所模拟的激素——的受体存在于部分肿瘤细胞表面，暗示药物可能直接作用于癌症的生物学过程本身。无论哪种机制最终得到证实，均对这类药物的长期医学与商业价值具有重要意义。</p><h2 style=\"text-align: left; padding-left: 10px;\"><strong>观察性研究局限不容忽视，确认仍需随机试验</strong></h2><p style=\"text-align: justify;\">尽管数据信号具有一致性，研究人员仍对现有研究的局限性保持审慎。</p><p style=\"text-align: justify;\">四项研究均依赖回顾性保险理赔记录和医疗数据库，存在固有偏差风险：被处方GLP-1药物的患者往往拥有更好的医疗资源获取渠道和更稳定的随访记录，这些因素本身就可能独立改善治疗结局，难以与药物效果剥离。</p><p style=\"text-align: justify;\">要确认GLP-1药物自身是否驱动了上述获益，需要通过随机对照试验——严格控制收入水平、基础健康状况及医疗资源差异的研究设计——加以验证。</p><p style=\"text-align: justify;\">目前，诺和诺德与礼来均未启动针对癌症适应症的专项研究。尽管如此，克利夫兰诊所癌症研究所副主席、相关研究的主导者Dr. Jaroslaw Maciejewski表示，横跨数十万患者的一致性数据&#34;很难被忽视&#34;。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LLII":"REX LLY Growth & Income ETF","LU0882574055.USD":"富达全球健康医疗A ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","ELIL":"2倍做多LLY ETF-Direxion","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","BK4007":"制药","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","ELIS":"1倍做空LLY ETF-Direxion","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4599":"减肥药","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1548497426.USD":"安联环球人工智能AT Acc","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LLY":"礼来","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LLYX":"2倍做多LLY ETF-Defiance","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","NVOX":"2倍做多NVO ETF-Defiance","LLYZ":"2倍做空LLY ETF-Defiance","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4516":"特朗普概念","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4585":"ETF&股票定投概念","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4588":"碎股","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","NVO":"诺和诺德","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"source_url":"https://wallstreetcn.com/articles/3772873","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2637336886","content_text":"四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。全球最畅销的减重与糖尿病药物或将迎来又一重大突破。四项新研究显示，诺和诺德的Ozempic和礼来的Mounjaro等GLP-1类药物，与癌症患者更好的治疗结局之间存在关联，可能进一步扩大这类已拥有数以千万用户的药物的市场前景，并为上述两家全球市值最高的制药公司提供新的增长动力。上述研究将于本月晚些时候在美国临床肿瘤学会（ASCO）年会上发布，涵盖逾数十万名患者的数据。其中规模最大的研究来自克利夫兰诊所癌症研究所，追踪逾1万名早期癌症患者，结果显示GLP-1药物使用者的癌症进展风险显著低于对比组——肺癌患者疾病进展率约减半，乳腺癌患者进展率同样从20%降至10%。另有研究显示，乳腺癌GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。若抗癌效益最终得到证实，将进一步巩固诺和诺德与礼来的行业地位。GLP-1药物已获批用于降低心脏病发作和中风风险，并正在测试对睡眠呼吸暂停及成瘾行为的疗效，抗癌效益将再度扩展这类药物的医学价值边界，并可能重塑其定价与报销逻辑。然而，研究人员明确指出，现有证据仅显示关联性，而非因果关系。四项研究均为回顾性观察研究，依赖保险理赔记录和医疗数据库，尚需随机对照试验加以确认。目前，诺和诺德与礼来均未针对GLP-1药物的抗癌效果开展专项临床研究。多癌种进展率大幅下降，数据信号一致克利夫兰诊所癌症研究所的研究将逾1万名确诊早期癌症后开始使用GLP-1药物的患者，与使用其他糖尿病药物的患者进行对比，结果显示GLP-1使用者的癌症扩散风险更低。具体数据颇为引人关注：肺癌患者中，进展为晚期的比例在GLP-1组约为10%，对比组为22%，降幅约50%；乳腺癌患者进展率分别为10%和20%；结直肠癌和肝癌亦呈现具有统计学意义的下降。\"鉴于数以百万计的美国人正在使用GLP-1类药物，我们显然迫切需要了解其潜在的抗肿瘤效果，\"将在ASCO年会上发布上述研究的克利夫兰诊所住院医生Dr. Mark Orland表示。未参与任何相关研究的Dana-Farber癌症研究所乳腺肿瘤学家Dr. Jennifer Ligibel表示，\"在多种癌症中，使用这些药物的人似乎癌症复发风险更低，这一发现确实令人瞩目。\"乳腺癌数据：发病率与生存率双双改善另外两项研究专门聚焦乳腺癌，从发病率和生存率两个维度考察GLP-1药物的潜在作用。德克萨斯大学MD安德森癌症中心对逾13.7万名乳腺癌患者的分析显示，GLP-1使用者的五年生存率超过95%，而非使用者为89.5%。宾夕法尼亚大学的研究纳入近9.5万名接受乳腺影像检查的女性，发现曾使用GLP-1药物者被诊断为乳腺癌的风险低约25%，这一差异在控制年龄、体重及其他风险因素后依然成立。MD安德森乳腺肿瘤学家、上述生存率研究的参与者Dr. Jasmine Sukumar表示：\"我们在多个数据库中都观察到了信号，这确实值得关注，因为这些研究的设计各有不同。\"作用机制存争议：代谢改善还是直接靶向肿瘤？科学界目前对GLP-1药物为何可能产生抗癌效果尚无定论，主要存在两种假说。其一，GLP-1药物通过推动减重和改善代谢健康间接降低癌症风险，而体重控制和代谢健康本身均与更低的癌症发病率独立相关。其二，GLP-1——即这类药物所模拟的激素——的受体存在于部分肿瘤细胞表面，暗示药物可能直接作用于癌症的生物学过程本身。无论哪种机制最终得到证实，均对这类药物的长期医学与商业价值具有重要意义。观察性研究局限不容忽视，确认仍需随机试验尽管数据信号具有一致性，研究人员仍对现有研究的局限性保持审慎。四项研究均依赖回顾性保险理赔记录和医疗数据库，存在固有偏差风险：被处方GLP-1药物的患者往往拥有更好的医疗资源获取渠道和更稳定的随访记录，这些因素本身就可能独立改善治疗结局，难以与药物效果剥离。要确认GLP-1药物自身是否驱动了上述获益，需要通过随机对照试验——严格控制收入水平、基础健康状况及医疗资源差异的研究设计——加以验证。目前，诺和诺德与礼来均未启动针对癌症适应症的专项研究。尽管如此，克利夫兰诊所癌症研究所副主席、相关研究的主导者Dr. Jaroslaw Maciejewski表示，横跨数十万患者的一致性数据\"很难被忽视\"。","news_type":1,"symbols_score_info":{"NVOH":0.6,"LLY":1.93,"NVOX":0.6,"LLYX":0.6,"ELIS":0.6,"LLYZ":0.6,"LLII":0.6,"ELIL":0.6,"NVO":1.94}},"isVote":1,"tweetType":1,"viewCount":525,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}